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Novel PMS2 Pseudogenes Can Conceal Recessive Mutations Causing
a Distinctive Childhood Cancer Syndrome
Michel De Vos,1 Bruce E. Hayward,1 Susan Picton,2 Eamonn Sheridan,3
and David T. Bonthron1
1Molecular Medicine Unit, University of Leeds, and Departments of 2Paediatric Oncology and 3Clinical Genetics, St. James’s University
Hospital, Leeds, United Kingdom
We investigated a family with an autosomal recessive syndrome of cafe´-au-lait patches and childhood malignancy,
notably supratentorial primitive neuroectodermal tumor. There was no cancer predisposition in heterozygotes; nor
was there bowel cancer in any individual. However, autozygosity mapping indicated linkage to a region of 7p22
surrounding the PMS2 mismatch-repair gene. Sequencing of genomic PCR products initially failed to identify a
PMS2 mutation. Genome searches then revealed a previously unrecognized PMS2 pseudogene, corresponding to
exons 9–15, within a 100-kb inverted duplication situated 600 kb centromeric from PMS2 itself. This information
allowed a redesigned sequence analysis, identifying a homozygous mutation (R802X) in PMS2 exon 14. Further-
more, in the family with Turcot syndrome, in which the ﬁrst inherited PMS2 mutation (R134X) was described, a
further truncating mutation was identiﬁed on the other allele, in exon 13. Further whole-genome analysis shows
that the complexity of PMS2 pseudogenes is greater than appreciated and may have hindered previous mutation
studies. Several previously reported PMS2 polymorphisms are, in fact, pseudogene sequence variants. Although
PMS2 mutations may be rare in colorectal cancer, they appear, for the most part, to behave as recessive traits. For
technical reasons, their involvement in childhood cancer, particularly in primitive neuroectodermal tumor, may have
been underestimated.
Introduction
Embryonal tumors of the CNS are a heterogeneous
group for which a precise diagnosis by morphological
criteria is problematic. Most common among them is
medulloblastoma, classically arising in the posterior
fossa, probably from cerebellar granule cells (Pomeroy
et al. 2002). Supratentorial primitive neuroectodermal
tumor (SPNET) is a rarer, aggressive embryonal tumor,
most likely derived from primitive neuroepithelial cells.
It has features that suggest that it is biologically and
genetically distinct from the histologically similar med-
ulloblastoma (Russo et al. 1999; Pomeroy et al. 2002).
SPNET has a poor prognosis, with median survival of
!2 years (Dirks et al. 1996), although there are indi-
cations that this may be improved with aggressive ther-
apy (Jakacki 1999; Yang et al. 1999; Strother et al.
2001).
Rather little is known about the molecular basis for
SPNET. It is usually sporadic and has not been com-
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monly reported in the major hereditary cancer syn-
dromes. There are, however, occasional exceptions. Pin-
eal or suprasellar primitive neuroectodermal tumor
(PNET) can occur in patients with germline RB1 mu-
tations (so-called “trilateral” retinoblastoma [MIM
180200]) (Paulino 1999). Also, childhood PNET can
occur in patients with germline TP53 mutations (Li-
Fraumeni syndrome [MIM 151623]) (Orellana et al.
1998), whereas somatic TP53 mutations have been
found in adult SPNETs (Ho et al. 1996). Central PNET
with features of rhabdoid differentiation can result from
germline INI1 (hSNF5) mutations (SMARCB1 [MIM
601607]) (Sevenet et al. 1999; Taylor et al. 2000).
There are at least two reports of PNET in neuroﬁbro-
matosis type 1 (NF1 [MIM 162200]). One of these tu-
mors was peripheral, developing in a preexisting plexi-
form neuroﬁbroma (Chan et al. 1996). The other was a
large SPNET that developed after chemo- and radio-
therapy for a brain stem astrocytoma (Raffel et al. 1989).
Most intracranial tumors in NF1, however, are glial in
origin, which raises the question of whether atypical tu-
mors, including medulloblastomas or SPNETs, may be a
pointer to a genetic disorder distinct fromNF1. Although
most children with cafe´-au-lait spots (CALS) do indeed
have NF1 (Korf 1992), the precise spectrum of tumors
attributable to NF1 remains unclear (Korf 2000), and
there are recent reports of an NF1-like phenotype in chil-
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Figure 1 Pedigree diagram. Linkage analysis was performed by
use of DNA from the eight numbered individuals (IV-1–IV-4, V-2–V-
4, V-6). Gray shading of the square representing patient V-6 indicates
that he has CALS but no tumor.
dren with unexpected tumors (Ricciardone et al. 1999;
Wang et al. 1999; Vilkki et al. 2001; Whiteside et al.
2002).
We report here on a heavily consanguineous family
showing cosegregation of cutaneous CALS and early-
onset brain tumors. This presentation led to an initial
diagnosis of NF1 (although the consensus criteria were
not met). Later, the clearly recessive inheritance pattern
suggested the likelihood of an alternative, unrecognized
cancer syndrome. Unexpectedly, the causative gene ul-
timately proved to be PMS2, prompting us to reconsider
the accepted role of this gene in tumor predisposition.
PMS2 is one of the mammalian genes similar to the
mutL DNA mismatch-repair (MMR) gene of Esche-
richia coli (Marti et al. 2002). The hMutLa heterodimer
of PMS2 with MLH1 (another mutL homologue) is the
major species providing mutL-like MMR activity in hu-
man cells (Li and Modrich 1995; Raschle et al. 1999;
Harfe and Jinks-Robertson 2000). PMS2-mutated hu-
man cells accordingly show a mutation rate equal to or
higher than that of MLH1-mutated cells (Kato et al.
1998). Despite this, although germline MLH1 muta-
tions are the most common cause of hereditary non-
polyposis colon cancer (HNPCC) (Peltomaki 2001),
PMS2 mutations are, in contrast, very rare, having been
reported in only ﬁve families with cancer (Nicolaides et
al. 1994; Hamilton et al. 1995; Miyaki et al. 1997; De
Rosa et al. 2000; Trimbath et al. 2001).
The existence of several pseudogenes corresponding
to the ﬁrst ﬁve or so exons of PMS2 has been recognized;
many of them are transcribed and could interfere with
both genomic and cDNA-based mutation analyses
(Horii et al. 1994; Nicolaides et al. 1995; Kondo et al.
1999). Reagents that allow discrimination between
PMS2 and these pseudogenes have been described (Ni-
colaides et al. 1995). The experience we report here,
however, suggests that even these may not permit a com-
prehensive genomic-based PMS2 mutation analysis and
that new studies of PMS2 are warranted to further ad-
dress its contribution to cancer predisposition.
Subjects and Methods
Clinical Features
Three siblings developed brain tumors in childhood
(ﬁg. 1). Patient V-1 presented with left hemiparesis in
1991 at the age of 10 years. A multifocal right cerebral
lesion with small-round-cell histology was classiﬁed as
a high-grade B-cell non-Hodgkin lymphoma. She had
had multiple CALS but was not personally examined,
since she died in 1992. Patient V-2 also had multiple
CALS. At 8 years of age, he presented with headaches
and diplopia. A right temporoparietal mass was sub-
totally resected and found to be a PNET. Patient V-4
had multiple CALS and mild learning difﬁculties. At 14
years of age, she presented with impaired consciousness.
A right frontal lobe lesion was resected and was again
found to be a SPNET. (Its karyotype was near-tetraploid,
with many cells also showing loss of one chromosome
13 and an unbalanced rearrangement resulting in 10q
loss.) A fourth family member (V-6) also has CALS and
mild learning difﬁculties; he is a double ﬁrst cousin (aged
10 years) of the proband and so far has no history of
cancer. No Lisch nodules or additional features of NF1
were present in any of the affected individuals. The par-
ents of both sibships were ﬁrst cousins. They were care-
fully examined and had no ocular or cutaneous signs of
NF1. Thus, neither the proband nor any other family
member met the diagnostic criteria for NF1 (National
Institutes of Health 1988). The CALS in affected indi-
viduals had a ragged-edged, slightly diffuse appearance,
not typical of the more sharply delineated CALS in NF1.
There was no family history of colorectal or endometrial
adenocarcinoma. Colonoscopy in patients IV-1 and IV-
2 was normal. Full informed consent for genetic inves-
tigations was obtained from all subjects or their parents,
and the studies were conducted under a protocol ap-
proved by the local ethics committee.
Linkage Analysis
The Weber human genome screening set, version 8
(Research Genetics), comprising 395 autosomal micro-
satellite markers at ∼10 cM density, was used for an
autozygosity search. PCR was performed on a RoboSeq
4200 automated biosystem (MWG Biotech), using 10-
ml reactions containing 60 ng genomic DNA, 1 mMprim-
ers, 250 mM each dNTP, 5 U Taq polymerase (Promega),
1.5–3.0 mM MgCl2, 10 mM Tris-HCl (pH 8.0), 50 mM
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Table 1
New PMS2-Speciﬁc Primers Used for Mutation Analysis
Exon PCR Primers
Protocol
(Mg2/mM) Sequencing Primer
3 F: ACTGATAGCATGGGTCCG, R: CAAAATTCTGAGACATGTGA c (1.5) …
4 F: ACACTGTCTTGGGAAATG, R: ATTAATTTTCAGAGAGGTTTC b (1.5) …
5 F: CTCAACCATTTAGATCTTGA, R: AATAAAGCATTTCTCAATAAT b (2.5) …
10 F: ATTAAGCCCTTCCGTATTT, R: GGAAACACATTAGCTAAAAGC b (1.5) F: CCTGTAATCCTAGCTACT
11 F: GACCAGTCCTGAACTCCTAGCC, R: GCTGCAGTGAGCCAAGATCA d (1.5) F: CAGTCCACATCTGAAAAA, R: CTCGCAGGAACATGTGGA
12 F: GTGTACAGGTCTGAAAACTTG, R: CGCCTGGCCAACTAGATA b (1.5) …
13 F: CACTTAGCTGAGTAGTGTTGTTATTT, R: TGAACACCTGAAAGAGAGGAAAC b (1.5) …
14 F: TCCAAAAAGCATTTTGTGAGTT, R: GAGTTCAAGGTCACAGAGAACG b (1.5) …
15 F: AACTACTAAAACGTTGAACC, R: TTTTTGAGACACAGTCTTGT a (2.0) …
KCl, and 0.1% Triton X-100. Cycling conditions were
95C for 120 s; 30 cycles of 94C for 45 s, 57C for 45
s, and 72C for 60 s; and 72C for 7 min. Products were
electrophoresed in multiplexed pools on an ABI 377 and
analyzed with GeneScan and Genotyper 1.1.1. Addi-
tional individual markers were analyzed by similar
methods.
Sequence Analysis of PMS2
Initially, we used primers (although with different buf-
fer conditions) that were developed to allow the speciﬁc
ampliﬁcation of the PMS2 exons while avoiding coam-
pliﬁcation of known pseudogene sequences (Nicolaides
et al. 1994, 1995). We obtained gene-speciﬁc amplicons
only for exons 1, 2, 6, 7, 8, and 9. New primers used
for other exons (table 1) were designed as directed by
multiple BLAST alignments (see below). Thermal cycling
conditions (on a PTC-200 [MJ Research]) were as fol-
lows:
a. 94C for 180 s; 35 cycles of 94C for 30 s, 49C
for 30 s, and 72C for 60 s;
b. 94C for 180 s; 35 cycles of 94C for 30 s, 52C
for 30 s, and 72C for 60 s;
c. 94C for 180 s; 8 cycles of 94C for 30 s, 58C
(1C/cycle) for 45 s, and 72C for 60s; 32 cycles
of 94C for 30 s, 50C for 45 s, and 72C for 60
s; and 72C for 420 s; and
d. 94C for 180 s; 8 cycles of 94C for 30 s, 63C
(1C/cycle) for 30 s, and 72C for 60s; and 34
cycles of 94C for 30 s, 55C for 30 s, and 72C
for 60 s.
PCR products were directly sequenced on both strands
by use of the BigDye (Applied Biosystems) or ET (Amer-
sham) dye-terminator cycle sequencing kits and ABI 377
or MegaBace 500 sequencers, respectively. Exon 13
products heterozygous for the 2184delTC mutation
were cloned to allow resolution of the two alleles.
Analysis of PMS2-Associated Repeat Elements
Following MegaBLAST genome searches (Mega-
BLASTWeb site), pairwise comparisons between regions
containing PMS2-related sequences were performed by
use of PipMaker (Schwartz et al. 2000) and Repeat-
Masker (RepeatMasker Web site). As described below,
all PMS2 pseudogenes are associated with a copy of a
∼17-kb sequence that we refer to as “PPJ” (pseudo-
PMS2-juxtaposed). A total of 20 PPJ copies exist on
chromosome 7. Two regions of the PPJ sequence, free
from high-copy repeat, were identiﬁed, and all 20 copies
of each were aligned by use of ClustalW (Thompson et
al. 1994). By use of PHYLIP (PHYLIP Web site), two
phylogenetic trees were constructed for each of these two
alignments: one by a parsimony method, one by a dis-
tance method, and both by bootstrapping. The group-
ings that were suggested from both aligned regions were
concordant. The distance trees demonstrated the exis-
tence of two main subgroups of PPJ repeats, each con-
taining nine members, and two outliers (at 4.78 Mb and
6.47 Mb).
Results
Linkage Mapping
The pedigree structure is shown in ﬁgure 1. Cytoge-
netic analysis (G-banding), including chromosome
breakage studies, had shown a normal karyotype in all
affected individuals. For purposes of linkage, patient V-
6, who has CALS but no tumor, was assigned as affected.
The three living affected individuals, one unaffected sib-
ling, and their four parents were analyzed for autozy-
gosity by use of 395 autosomal markers. Two regions
were concordantly homozygous in the three affected in-
dividuals: 9q34.3 (D9S158) and 7p22.1 (GATA24F03
[D7S1819 and D7S517], 4.14 Mb). The 9q region was
eliminated by demonstrating heterozygosity for closely
ﬂanking markers D9S1818 and D9S1838. In contrast,
two additional 7p22.1 markers, D7S481 (5.78 Mb) and
D7S511 (4.35 Mb), were found to be concordantly ho-
mozygous. Multipoint analysis of the entire genome-
search data set conﬁrmed that this was the only genomic
region with a LOD score 13. It is signiﬁcant that this
homozygous region includes the location of the PMS2
MMR gene (5.7 Mb).
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Figure 2 a, Mutation analysis of PMS2 exon 14 (ABI377). For-
ward (F) and reverse (R) strand sequences are shown of uncloned PCR
products generated by use of the published primer pair (upper panels)
or the redesigned PMS2-speciﬁc primers (lower panels). The mutated
codon is boxed, and the arrows indicate the mutated nucleotide. b,
Exon 13 mutation in the patient with Turcot syndrome (Hamilton et
al. 1995) (MegaBace). PCR products were cloned to show both deleted
(top) and normal alleles. The lowercase nucleotides are the end of
intron 12. The deleted dinucleotide (within a 2-nt repeat) is underlined,
and the resulting predicted novel C-terminus is italicized.
Mutation Analysis
Sequencing of PMS2 was initially performed by use
of published PCR primers (Nicolaides et al. 1995). Am-
pliﬁcation of exons 10 and 11 failed, and no sequence
variants unique to the affected individuals were found
in the remaining exons. The strong genetic evidence im-
plicating this locus, however, prompted close examina-
tion of the patient sequences. Compared with the pub-
lished PMS2 cDNA sequence, a number of apparently
heterozygous or homozygous base changes were ob-
served, in the amplicons for exons 3, 4, 5, 13, and 14.
These were consistently present in both unaffected and
affected individuals. The appearance of heterozygous
changes within an autozygous region suggested that
there might still be coampliﬁcation of two or more tar-
gets. This is probably attributable at least in part to the
fact that we had not employed the unusual PCR buffer
conditions of the original report (Nicolaides et al. 1995);
these conditions are necessary to obtain PMS2-speciﬁc
products (B. Vogelstein, personal communication). Even
so, the previously reported partial PMS2 pseudogenes
(Horii et al. 1994; Nicolaides et al. 1995; Kondo et al.
1999) did not explain the anomalous results for exons
13–14. We therefore performed a search for all PMS2-
related sequences in the draft genome sequence. As de-
tailed below, this identiﬁed 14 pseudogenes, each cor-
responding to most or all of the PMS2 exon 1–5 region.
(Some of these correspond to the pseudogenes previously
identiﬁed by others.) However, in addition, we identiﬁed
a novel 100-kb genomic duplicon containing copies of
exons 9 and 11–15. All of these pseudogenes are located
on chromosome 7.
Alignment of the sequences of PMS2 and all of these
pseudogenes allowed the design of completely speciﬁc
PCR primer pairs for exons (3–5, 10–15) that had pre-
viously failed or had coampliﬁed with pseudogene se-
quences. After sequencing the new amplicons, a ho-
mozygous 2428CrT mutation was found in exon 14 of
PMS2 in all three affected individuals. This is a nonsense
mutation (R802X). Figure 2 shows a comparison be-
tween the exon 14 sequences obtained by use of the new
speciﬁc primers and the published pair. All four parents
and the unaffected sibling were heterozygous for this
mutation. The original mutation analysis failed to detect
the R802X mutation because, under the conditions we
used, the original primers actually preferentially amplify
the previously unrecognized pseudogene (which we refer
to below as “w0”).
Recessive Inheritance of Turcot Syndrome
The ﬁrst report of an inherited PMS2 mutation was
in siblings with Turcot syndrome (MIM 276300) (Ham-
ilton et al. 1995). Both had inherited a heterozygous
R134X mutation from their unaffected father. We won-
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dered whether this might indicate that R134X, like
R802X, is a recessive mutation, and we looked for a
second mutation by genomic analysis, as described
above. A heterozygous 2-bp deletion was found in exon
13, within a repeated dinucleotide (CTCT) at codon
728–729 (2184delTC). This brings a stop codon in
frame after ﬁve novel amino acid residues. The mutation
was conﬁrmed by sequencing cloned PCR products (ﬁg.
2b), and its speciﬁcity for PMS2 exon 13 (as opposed
to w0) was conﬁrmed by the presence of TTT, rather
than TTC, at codon 751 in these clones. Both siblings
were compound heterozygotes (R134X/2184delTC),
and 2184delTC was conﬁrmed to be maternal in origin
by analysis of both parental DNAs.
Distribution and Evolution of PMS2 Pseudogenes
A number of studies have demonstrated the existence
of a family of transcripts similar to PMS2 and their
corresponding genomic sequences (related to PMS2 ex-
ons 1–5) on chromosome 7q (Horii et al. 1994; Nico-
laides et al. 1995; Osborne et al. 1997; Chadwick et al.
2000; Valero et al. 2000). However, the full extent of
this family has not been systematically examined by use
of recent whole-genome sequence data. To ensure the
speciﬁcity of our mutation analysis, we ﬁrst performed
a BLAST search of the human genome with the PMS2
reference cDNA NM_000535. This revealed a total of
15 pseudogene loci on chromosome 7, none of them
processed. In addition to PMS2 itself (15 exons), there
is one locus (w0) containing exons 9 and 11–15 and 14
loci (w1–w14) that each contain some or all of exons 1–
5. There are no recognizable pseudogenes on other chro-
mosomes. A search of the mouse genome with the ref-
erence mouse cDNA showed no evidence for comparable
intrachromosomal duplications.
Some of the w1–w14 loci lie in close proximity, in a
pattern that suggested that the ∼7-kb PMS2 genomic
fragment containing exons 1–5 was part of a larger du-
plicated structure at the pseudogene loci. In fact, further
analysis showed that all of these pseudogenes (w1–w14)
are part of a larger sequence of ∼23 kb (including the
PMS2 section), with the PMS2 section located at one
end of the 23-kb block. It is curious that, despite being
a feature common to all of the pseudogenes (w1–w14),
the ∼16 kb of genomic sequence 3′ to the (w1–w14) exons
is not present in the PMS2 gene itself. We refer to this
∼16-kb element as a PPJ element. Further BLAST search-
ing revealed eight additional PPJ copies that are not as-
sociated with a 7-kb PMS2 exon 1–5 pseudogene seg-
ment. Two of these (comparatively poorly conserved)
are on chromosome 17, and the others are on chro-
mosome 7. One is in close proximity to the 5′ end of
the w0 pseudogene (see below).
The distribution of the PPJ repeats (indicated by block
arrows) is represented in ﬁgure 3. For insight into the
mechanism of dispersal of the PPJ elements and their
associated pseudogenes, two nonredundant segments of
sequence were used for a phylogenetic comparison be-
tween all 20 of the chromosome 7 PPJ copies. A distance-
based tree (ﬁg. 4) shows that they fall into three groups
(indicated in ﬁg. 3 as arrows of different colors). Their
mechanism of dispersal appears complex. In some cases,
there is evidence for local endoreduplication (e.g., PPJ
elements associated with w2-w3 and w6-w7-w8), but, in
another case (w11-w12), PPJ elements that are evolu-
tionarily divergent are juxtaposed, suggesting transpo-
sition or recombinational joining of different PPJ arrays.
There are also several different examples of PPJ dis-
persal via intrachromosomal duplication of larger seg-
ments containing them. Some of these were previously
described (as “type A” and “type C” repeats) in an anal-
ysis of the repeated sequences that ﬂank the Williams
syndrome deletion region (Valero et al. 2000). However,
there are also three novel sets of large (∼100-kb) du-
plicons. One of these contains the exon 9–15 pseudogene
(w0) and 3′ ﬂanking region, in inverted orientation ∼740
kb upstream of PMS2. Another duplicon (associated
with w10 and w11-w12) contains the DTX2 and UPK3B
genes. A third (containing the non-PMS2-associated PPJ
elements at 43.70 Mb, 100.69 Mb, and 100.79 Mb)
contains the calcium-promoted Ras inactivator gene
(RSGP5, CAPRI). Thus, there are ﬁve different large
duplicons associated with PPJ elements on chromosome
7. Only 3 of the 20 PPJ elements are not part of one of
these larger duplicons. The close similarity of the w2 and
w3 PPJ elements and of the w6, w7, and w8 PPJ elements
to each other further suggests that each of these clusters
originated subsequent to the larger-scale genomic du-
plications around theWilliams syndrome deletion region
(ﬁg. 4).
Discussion
Phenotype
Although CALS are the hallmark lesion of NF1, their
presence alone does not establish the diagnosis (National
Institutes of Health 1988). Nonetheless, this is the di-
agnostic label applied to most children with CALS (Bur-
well et al. 1982; Korf 1992), including, initially, the chil-
dren in the family described here. It is accepted that
patients with NF1 have an increased risk of malignancy
(Korf 2000)—most commonly, peripheral malignant
nerve sheath tumors and glial tumors, including astro-
cytomas (Baptiste et al. 1989). CNS neoplasms (other
than neuroﬁbromas and optic gliomas) occurred in 2%
of NF1 probands in a large national series (Friedman
and Birch 1997), and there have also been other sug-
gestions of an association betweenmedulloblastoma and
Figure 3 Distribution of PMS2 pseudogenes and related sequences on chromosome 7. Symbols are as deﬁned in the key. The members
of the pseudogene-associated repeat family (PPJ repeats) can be classiﬁed by sequence similarity into two main subgroups (indicated by white
and gray block arrows) and two outlying members (turquoise). The type 1 members (gray) appear to be the younger of the two main PPJ
subgroups, having (with the exception of the w13-associated PPJ element) shorter distance branches on the phylogeny tree. Larger blocks of
different colors indicate different higher-order repeat elements. Those shown in yellow and green correspond, respectively, to the type A and
type C repeat elements identiﬁed elsewhere in studies of the Williams syndrome deletion region (Valero et al. 2000). (Other large repeat blocks
in this region that are not associated with PPJ elements are not shown.) Numbers indicate the approximate positions (in Mb) of each PPJ
element on the draft genome sequence (build 33).
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Figure 4 Phylogenetic tree illustrating the relationships between
the different members of the family with the 23-kb PPJ element. The
tree was generated by using the DNADIST algorithm of the PHYLIP
package to analyze a ClustalW-generated alignment of all 20 copies
of a ∼1.5-kb segment of the PPJ element. (Details are available on
request.) Branch lengths, therefore, give an indication of degree of
divergence. The pseudogene-associated PPJ elements are referred to by
the corresponding identity (e.g., w1). Those not associated with a pseu-
dogene are given a number representing their sequence coordinate on
chromosome 7 (National Center for Biotechnology Information
[NCBI] release 33). The inset shows a tree generated from a subset of
these PPJ elements by use of the same algorithm, to show more clearly
the interrelationships of the closely similar w2–w8 PPJ elements. The
structure of this tree implies that the local duplications leading to these
PPJ clusters (and, hence, associated pseudogene clusters) occurred after
the large-scale (∼100-kb) duplications around the Williams syndrome
deletion region.
NF1 (Perilongo et al. 1993; Martinez-Lage et al. 2002).
In the family described here, however, none of the af-
fected individuals met the National Institutes of Health
consensus criteria. Furthermore, the pedigree structure
strongly suggested a recessive disorder. This experience
shows that diagnostic caution is needed when patients
present with the constellation of brain tumors and
CALS.
Five recent reports demonstrate the association of ho-
mozygous loss of MMR function with the combination
of CALS and early-onset neoplasia (particularly hema-
tological). This phenotype has been observed with mu-
tation of MLH1 (Ricciardone et al. 1999; Wang et al.
1999; Vilkki et al. 2001), MSH2 (Whiteside et al. 2002),
and PMS2 (Trimbath et al. 2001). In the families with
MLH1 mutations (Ricciardone et al. 1999; Wang et al.
1999; Vilkki et al. 2001), there were phenotypes con-
sistent with HNPCC in heterozygotes. The family re-
ported here, in contrast, has no features suggesting
HNPCC, nor any other clear heterozygote effect. The
phenotype is one of CALS with brain tumors, typical
neither of NF1 nor of HNPCC. This presentation ap-
pears highly characteristic, and we propose that it should
be considered indicative of a disorder caused by recessive
mutations in MMR genes, not of NF1. In isolated cases,
however, the recognition of this phenotype could be
problematic, especially since up to half of NF1 cases
result from new mutations (Ruggieri and Huson 2001).
It is thus very likely that other individuals with this dis-
order will have been misdiagnosed with NF1. SPNET,
a rare tumor not usually found in the context of cancer-
predisposition syndromes, is a particularly striking fea-
ture of the present family. It remains to be determined
whether PMS2 mutations are a frequent underlying fac-
tor in nonfamilial PNET.
Genetic Behavior of PMS2 Mutations
Inherited mutations of PMS2 have been described in
only ﬁve families, whereas mutations of its partner
MLH1 are a frequent cause of HNPCC (Peltomaki
2001). This discrepancy has never been adequately ex-
plained. In particular, current biochemical knowledge
does not support the idea that functional redundancy
among the possible MLH1 partners (PMS1, PMS2, and
MLH6) underlies the rarity of PMS2mutations in cancer
families (Li andModrich 1995; Kato et al. 1998; Raschle
et al. 1999; Harfe and Jinks-Robertson 2000).
Critical review of known families (table 2) suggests
that PMS2 mutations behave as recessive traits. In four
families (Hamilton et al. 1995; De Rosa et al. 2000;
Trimbath et al. 2001), there are homozygous or com-
pound heterozygous truncating mutations, with little or
no evidence of cancer predisposition in heterozygotes.
Mutation 2361delCTTC (De Rosa et al. 2000) truncates
the protein at amino acid 788, and it is the most similar
mutation to the R802X mutation in the present family.
These mutations may remove the ability to interact with
MLH1 through the PMS2 C-terminal domain (amino
acids 675–850), deﬁned elsewhere by in vitro studies
(Guerrette et al. 1999). It is interesting to note that there
is good existing evidence that R802X is a biochemically
null mutation. This mutation was previously found in
the HEC-1-A and HEC-1-B endometrial cancer cell lines
(Kuramoto et al. 1972; Risinger et al. 1995). The
R802X-hemizygous HEC-1-A line is almost completely
lacking in MMR activity, unlike HEC-1-B, which also
retains a normal PMS2 allele (Glaab et al. 1998). This,
along with the correction of the severe microsatellite
instability in HEC-1-A by reintroduction of functional
PMS2 (Risinger et al. 1998), conﬁrms that R802X is a
null mutation.
Evidence for dominant PMS2 mutations is less con-
vincing. The R134X mutation (Hamilton et al. 1995)
displayed a dominant negative effect on MMR in ham-
ster ﬁbroblasts, but not in human ﬁbroblasts (Nicolaides
et al. 1998; Yamada et al. 2003). Despite this, the clinical
data were more suggestive of recessive inheritance, and
we have now conﬁrmed the presence of a second trun-
cating mutation on the other allele in this patient. Het-
De Vos et al.: Cryptic PMS2 Mutations in Childhood Cancer 961
Table 2
Genetic and Clinical Summary of Reported Familial PMS2 Mutations
Mutation Exon Inheritance
11 Sibling
Affected? Tumor Type Reference
R802X 14 PMS2-speciﬁc Recessive Yes PNET, non-Hodgkin lymphoma Present study
1145ins20a 10/11 junction Recessive Yes CALS, colon cancer, acute lymphoblastic leukemia,
astrocytoma, ovarian neuroectodermal tumor,
endometrial cancer, “brain tumor”
Trimbath et al. 2001
1221delG, 2361delCTTC 11b, 14b Recessive Yes Oligodendroglioma, colon cancer, neuroblastoma De Rosa et al. 2000
R134X, 2184delTC 5, 13 Recessivec Yes CALS, glioblastoma, colon cancer, non-Hodgkin
lymphoma
Hamilton et al. 1995;
present study
E705K 12 Recessived No Astrocytoma, lymphoma, colon cancer Miyaki et al. 1997
a Renumbered from original reference, according to 1 p A of initiator codon.
b On the basis of presented data, one cannot absolutely exclude the possibility of this mutation being within the w0 pseudogene.
c Dominant inheritance was initially suggested, but clinical data are more consistent with recessive inheritance (see text and also discussion in Liu et al.
2001).
d Only one heterozygous mutation was found, but data are consistent with recessive inheritance (see text).
erozygous mutation E705K was reported in another pa-
tient with Turcot syndrome (Miyaki et al. 1997), but,
as with R134X, this mutation was inherited from a clin-
ically unaffected parent, who also lacked the constitu-
tional MMR defect present in the patient. Miyaki et al.
therefore suspected an undetected mutation on the pa-
tient’s other allele. A classical, “two-hit” (germline and
somatic) loss of tumor-suppressor function was found
in the ﬁrst reported case of PMS2-related HNPCC (Ni-
colaides et al. 1994), but it is not clear if the germline
mutation was inherited.
All in all, there remains no convincing evidence dem-
onstrating segregation of the heterozygous PMS2 mu-
tation with a cancer-predisposition syndrome. Mice het-
erozygous for a Pms2 disruption do not exhibit increased
spontaneous mutagenesis, again suggesting that Pms2-
related genetic instability may be recessive (Narayanan
et al. 1997). In contrast, present evidence indicates that
recessively inherited PMS2 pathology is a clearly deﬁned
entity and could be implicated in unusual types of ne-
oplasm, particularly in childhood.
Pseudogenes Confounding Previous Studies of PMS2
in Cancer
Our experience suggests that some previous PMS2
mutation analyses may have suffered both from failure
to detect pathogenic mutations and from misinterpre-
tation of sequence changes within the pseudogene exons.
The following speciﬁc points may be highlighted:
1. The w0 exon 12 and 15 sequences are identical to
those of PMS2. Previous analyses of these exons
could not have distinguished which target was be-
ing analyzed.
2. The w0 exons 13 and 14 each contain a single
nucleotide substitution. Both of these (codon 751
TTTrTTC and codon 775 AACrAGC) have been
reported elsewhere as polymorphisms (Basil et al.
1999). (Observed heterozygosities 150% could
have indicated the true nature of the sequence
changes.) Sequence comparison predicts that nei-
ther the primers used by Basil et al. (1999) nor
those of Nicolaides et al. (1995) would be selective
for the real PMS2 exons 13–14. Our own expe-
rience, in fact, suggests that the published primers
may, under some conditions, preferentially amplify
pseudogene sequences (ﬁg. 2). Again, therefore,
some previous analyses of these exons in families
with cancer may not have distinguished pseudo-
gene and PMS2 targets.
3. The large w0 exon 11 differs at 23 positions from
PMS2. Again, two of these (codon 479 CACrCAG,
codon 496 CACrCAT) were reported as PMS2
polymorphisms (Basil et al. 1999), whereas anom-
alous PCR results pointed others to the existence of
an exon 11 pseudogene (Chadwick et al. 2000). The
latter authors concluded that the exon 11 pseudo-
gene was not transcribed since no correspondingRT-
PCR product was obtainable (Chadwick et al.
2000), but, unfortunately, an RT-PCR primer lo-
cated in exon 10 was used. Our ﬁnding, that exon
10 is missing from w0, explains the failure to detect
pseudogene transcripts. EST databases show ap-
proximately equal numbers of spliced transcripts
representing w0 and the corresponding region of
PMS2. The w0 (9–15) pseudogene is therefore tran-
scribed, and it will interfere with cDNA-based
screens for PMS2 mutations, not just those based
on genomic PCR.
4. The location of the ∼100-kb inverted repeat asso-
ciated with w0 raises the interesting possibility that
an inversion could occur through intrachromosomal
recombination between this repeat and its PMS2-
associated copy. An inversion polymorphism of this
kind is known to result from recombinationbetween
the inverted repeats ﬂanking the Williams-Beuren
syndrome critical region (WBSCR) (Osborne et al.
2001). Such an inversion would not physically dis-
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rupt PMS2 unless its breakpoint occurred within the
much smaller ∼16-kb segment of the repeat that lies
upstream of exon 15.
In conclusion, we suggest that the role of PMS2 as a
familial cancer gene merits reexamination. In light of
present evidence, PMS2 mutations are more likely to re-
sult in a recessively inherited childhood cancer syndrome
than in a “classical” autosomal dominant HNPCC-type
disease.
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